×
About 305 results

Pfizer Vaccine Protection Wanes After 6 Months: Study
https://www.medscape.com/viewarticle/955601

Jul 28th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Pfizer's COVID-19 vaccine continues to show strong protection against serious illness and hospitalization after 6 months, but overall protection against the virus appears to wane after a half a year, according to a new study. The July 28 preprint report ...

FDA Approves Pfizer's COVID Vaccine
https://www.medpagetoday.com/infectiousdisease/covid19vaccine/94167

Aug 23rd, 2021 - The FDA approved the Pfizer/BioNTech COVID-19 vaccine on Monday, the first vaccine against the novel coronavirus to receive full approval. The vaccine will be marketed as Comirnaty, and can be used for individuals ages 16 and older to prevent COVID-19. However, the vaccine is still under emergency use authorization (EUA) for adolescents ages 12-15, the ...

Do You Want a COVID-19 Booster Shot?
https://www.medscape.com/viewarticle/955976

Aug 4th, 2021 - When Pfizer in early July announced intentions to file for US Food and Drug Administration (FDA) authorization of a third, booster dose in addition to its two-shot COVID-19 vaccine regimen, the Centers for Disease Control and Prevention, the FDA, and the National Institutes of Health were quick to issue a joint statement saying that they would decide when the timing is right for A...

Vaccinated but Sick With COVID-19
https://www.medpagetoday.com/infectiousdisease/covid19/90584

Jan 7th, 2021 - Some healthcare workers have reported falling ill with COVID-19 after getting their first vaccine dose -- but that's not a surprise, as protection can take as long as 2 weeks to kick in, researchers said. A nurse from California made headlines last week after getting sick 6 days after he received his first shot. Since then, other healthcare workers have shared similar exper...

CDC and Pfizer at Odds Over Need for COVID-19 Booster Shots
https://www.medscape.com/viewarticle/954530

Jul 9th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Shortly after Pfizer announced its intention to seek FDA authorization for a third COVID-19 vaccine shot on Thursday, the CDC, FDA, and NIH countered with a joint statement the same day saying, essentially, it's still too soon. In a battle of the booster shot statements, the vac...

Moderna Says Vaccine 90% Effective After 6 Months
https://www.medscape.com/viewarticle/949287

Apr 14th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Moderna says its coronavirus vaccine provides strong protection up to 6 months after a second dose. "Updated cases show continued strong efficacy, including greater than 90% against cases of COVID-19 and greater than 95% against severe cases of COVID-19, with approxim...

Delta Variant Key to Breakthrough Infections in Vaccinated Israelis
https://www.medscape.com/viewarticle/954357

Jul 7th, 2021 - Updated July 8, 7:15 pm // This story has been updated to show that Pfizer will seek an FDA EUA for a booster to its COVID vaccine prompted by new data from Israel. Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Pfizer announced Thursday that it will seek US Food and Drug Administration (FDA) authorization for a booster ...

Fauci Says He Won't Take an Antibody Test
https://www.medscape.com/viewarticle/954115

Jul 1st, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. America's COVID-19 doctor, Anthony Fauci, MD, says he won't bother taking an antibody test to find out whether he needs a coronavirus vaccine booster shot. "If I went to LabCorp or one of those places and said, 'I would like to get the level of anti-spike antibodies,' I could tell what my...

How Long Does the Vaccine Protect Me?
https://www.medscape.com/viewarticle/949832

Apr 23rd, 2021 - Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. JOHN WHYTE: Hi, everyone. I'm Dr. John Whyte, Chief Medical Officer at WebMD. Just how long are you protected from COVID after vaccination? Here's what you need to know in 60 seconds. Both Pfizer and Moderna studied the immune function of people that were vaccinated six months ago. And wha...

A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults.
https://doi.org/10.1056/NEJMoa1614474
The New England Journal of Medicine; Ostergaard L, Vesikari T et. al.

Dec 14th, 2017 - MenB-FHbp is a licensed meningococcal B vaccine targeting factor H-binding protein. Two phase 3 studies assessed the safety of the vaccine and its immunogenicity against diverse strains of group B meningococcus. We randomly assigned 3596 adolescents (10 to 18 years of age) to receive MenB-FHbp or hepatitis A virus vaccine and saline and assigned 3304 young adults (18...

Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against p...
https://doi.org/10.1016/S0140-6736(14)60934-X
Lancet (London, England); John J, Giri S et. al.

Jul 16th, 2014 - Intestinal immunity induced by oral poliovirus vaccine (OPV) is imperfect and wanes with time, permitting transmission of infection by immunised children. Inactivated poliovirus vaccine (IPV) does not induce an intestinal mucosal immune response, but could boost protection in children who are mucosally primed through previous exposure to OPV. We aimed to assess the e...

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522799
The New England Journal of Medicine; Chemaitelly H, Tang P et. al.

Oct 7th, 2021 - Waning of vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The persistence of BNT162b2 (Pfizer-BioNTech) vaccine effectiveness against infection and disease in Qatar, where the B.1.351 (or beta) and B.1.617.2 (or delta) variants have dominated incidence and polymerase-chain...

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated he...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489881
Lancet (London, England); Tartof SY, Slezak JM et. al.

Oct 8th, 2021 - Vaccine effectiveness studies have not differentiated the effect of the delta (B.1.617.2) variant and potential waning immunity in observed reductions in effectiveness against SARS-CoV-2 infections. We aimed to evaluate overall and variant-specific effectiveness of BNT162b2 (tozinameran, Pfizer-BioNTech) against SARS-CoV-2 infections and COVID-19-related hospital admissions...

COVID Vaccine Effectiveness 'Waning Over Time'
https://www.medscape.com/viewarticle/957202

Aug 25th, 2021 - Protection provided by two doses of the Pfizer-BioNTech and the AstraZeneca/Oxford COVID vaccines wanes within 6 months, according to new research. An analysis by the ZOE COVID study suggested that a "worst case scenario" could see protection reduced to below 50% for healthcare workers and the elderly, who were among the first to be vaccinated. I...

Antibodies Fade Faster After Vaccine vs Actual Infection
https://www.medscape.com/viewarticle/957089

Aug 24th, 2021 - (Reuters) - Protective antibody levels decline faster in recipients of the mRNA COVID-19 vaccine from Pfizer/BioNTech than in COVID-19 survivors, according to doctors at one of Israel's largest HMOs. The research team tracked antibody levels in 2,653 adults who received two doses of the vaccine and in 4,361 COVID-19 survivors who were never vaccinated. Antibody levels fell ...

Delta Variant Acquitted in Need for Pfizer Boosters. Kind Of.
https://www.medpagetoday.com/infectiousdisease/covid19vaccine/94841

Oct 4th, 2021 - A decline in the effectiveness of the Pfizer COVID-19 vaccine (Comirnaty) against infection appeared to be due to waning immunity, not the Delta variant, researchers found. Examining sequenced infections, protection against infection with the Delta variant was 93% (95% CI 85-97) for the first month following full vaccination but then dropped to 53% (95% CI 39-65) after 4 months...

Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine - Adviso...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657641
MMWR. Morbidity and Mortality Weekly Report; Patton ME, Stephens D et. al.

May 19th, 2017 - Two serogroup B meningococcal (MenB) vaccines are currently licensed for use in persons aged 10-25 years in the United States. The two vaccines are MenB-FHbp (Trumenba, Pfizer, Inc.) (1) and MenB-4C (Bexsero, GlaxoSmithKline Biologicals, Inc.) (2). In February 2015, the Advisory Committee on Immunization Practices (ACIP) recommended use of MenB vaccines among certain groups...

Pfizer's Vaccine Protection May Wane After 2 Months
https://www.medscape.com/viewarticle/960553

Oct 8th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. The protection from Pfizer's COVID-19 vaccine may begin to wane against infection after 2 months, but it still prevents hospitalization and death for at least 6 months, according to two new studies published Wednesday in The New England Journal of Medici...

Pfizer COVID Vaccine Antibodies May Disappear in 7 Months, Study Says
https://www.medscape.com/viewarticle/960214

Oct 4th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Antibody levels may wane after 7 months for people who got the Pfizer-BioNTech vaccine, according to a new study published on the bioRxiv preprint server. In the study, which hasn't yet been peer-reviewed or formally published in a medical journal, researchers analyzed blood...

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8459899
MMWR. Morbidity and Mortality Weekly Report; Self WH, Tenforde MW et. al.

Sep 24th, 2021 - Three COVID-19 vaccines are authorized or approved for use among adults in the United States (1,2). Two 2-dose mRNA vaccines, mRNA-1273 from Moderna and BNT162b2 from Pfizer-BioNTech, received Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) in December 2020 for persons aged ≥18 years and aged ≥16 years, respectively. A 1-dose viral vector vacc...